AnaptysBio, Inc. (NASDAQ:ANAB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

ANAB has been the topic of several other reports. JMP Securities reaffirmed an “outperform” rating and set a $45.00 target price on shares of AnaptysBio in a research report on Friday, March 31st. Credit Suisse Group reaffirmed an “outperform” rating and set a $34.00 target price on shares of AnaptysBio in a research report on Tuesday, April 18th. Wedbush reduced their target price on AnaptysBio from $33.00 to $28.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 29th. Robert W. Baird initiated coverage on AnaptysBio in a research report on Monday, July 10th. They set an “outperform” rating and a $36.00 target price on the stock. Finally, Stifel Nicolaus upped their target price on AnaptysBio from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, May 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $35.60.

AnaptysBio (NASDAQ ANAB) traded up 6.874% during midday trading on Monday, hitting $28.065. The company had a trading volume of 47,298 shares. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $29.96. The stock has a 50 day moving average price of $24.76 and a 200-day moving average price of $24.38. The stock’s market capitalization is $568.85 million.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Thursday, May 11th. The biotechnology company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by $0.57. On average, equities analysts predict that AnaptysBio will post ($2.48) EPS for the current year.

WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/17/anaptysbio-inc-nasdaqanab-upgraded-to-hold-by-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently made changes to their positions in ANAB. Bank of America Corp DE purchased a new position in shares of AnaptysBio during the first quarter worth $123,000. TIAA CREF Investment Management LLC purchased a new position in shares of AnaptysBio during the first quarter worth $227,000. Endurant Capital Management LP purchased a new position in shares of AnaptysBio during the first quarter worth $258,000. Bank of New York Mellon Corp purchased a new position in shares of AnaptysBio during the first quarter worth $373,000. Finally, Monashee Investment Management LLC purchased a new position in shares of AnaptysBio during the first quarter worth $694,000. 72.59% of the stock is currently owned by institutional investors and hedge funds.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.